Obesity

Would your patients on GLP-1 RAs benefit from nutrition support? OPTIFAST VLCD products can help meet nutritional requirements when appetite is affected by GLP-1 RA therapy.

This retrospective review evaluates real world clinical experience of concomitant use of meal replacement products and GLP-1 RAs in Australia and South Africa. The results illustrate that this combination for weight management is feasible in real-life and may offer potential advantages for weight management.

This study aimed to determine the demographic, eating, self‐efficacy and program engagement characteristics of VLCD users in Australia (regular vs. intermittent users) and associations with self‐perceived program success on weight loss, quality of life (QOL), mental health and physical health.

The OPTIFAST Diabetes Management Guidelines have been developed to assist healthcare professionals manage patients with diabetes and excess weight who may be at greater health risk.

Learn about new Australian clinical evidence on the impact of the very low energy diets for Type 2 Diabetes remission. The DiRECT-Aus trial confirms that that an intensive lifestyle intervention (very low energy diet) delivered in an Australian primary care setting to individuals with recently diagnosed type 2 diabetes results in remission for one in two participants. The study was supported by Diabetes Australia (not-for-profit organisation), and 5 public health networks. Nestlé Health Science donated OPTIFAST VLCD product for the duration of the trial.   Click here to view the video.

Proceedings from a webinar from the 81st American Diabetes Association discusses the current and emerging novel non-pharmacological approaches to the prevention and remission of type 2 diabetes, weight management, and CV risk reduction.

Lifestyle interventions are an important component of any pharmacological and surgical treatment. One such lifestyle intervention for weight management is Intermittent Fasting. These guidelines have been developed to provide guidance to healthcare professionals in the use of the OPTIFAST VLCD Program for Intermittent Fasting.

An online resource which lists low carbohydrate vegetables, beverages, condiments & sauces that are permitted on the Intensive Level of the OPTIFAST Very Low Calorie Diet Program. These additional low calorie foods can help add variety and assist in compliance for those who are utilising the OPTIFAST VLCD program. Additionally, foods that should be avoided are also listed.

An online patient brochure explaining what protein is and the importance of optimal protein intake during the process of weight loss. The brochure also outlines the key features and benefits of OPTIFAST VLCD Protein Plus Shake products and how patients can utilise the Protein Plus Shake products as part of the OPTIFAST VLCD Program.

This online resource is a patient information booklet highlighting the VLED diet required 2 weeks before bariatric surgery including sample meal plans and recipes. This pre-bariatric surgery patient information booklet covers why the diet is necessary pre-surgery as well as some of the challenges that patients completing the VLED may come across.

This product range card provides a list of nutritional information and ingredients lists of OPTIFAST VLCD products that are available for purchase and consumption in New Zealand. The following RESOURCE provides nutritional information for products from the OPTIFAST VLCD shakes, bars, desserts as well as soups range.

This product range card provides a list of nutritional information and ingredients lists of OPTIFAST VLCD products that are available in Australia. The following RESOURCE provides nutritional information for products from the OPTIFAST VLCD shakes, bars, Protein Plus shakes, desserts as well as soups range.

Summary of evidence focusing on the benefits of weight loss before bariatric surgery.

A protocol addressing the dietary management of overweight and obesity in female and male infertility, pregnancy, inter and postpartum, endometriosis and polycystic ovarian syndrome patients using the OPTIFAST VLCD Program. The protocol also provides information on what the the OPTIFAST VLCD Program is, how it has been developed and reviews clinical evidence for the conditions above.

A pre-operative protocol addressing obesity management pre & post-bariatric surgery and general surgical procedures to minimise surgical and post-surgical risks. The protocol highlights the fact that with the increase in bariatric surgeries being performed, there is an increased need for preoperative weight loss. This has been driven by the necessity to optimise the safety of surgery.

A protocol addressing treatment guidelines for those with co-morbidities: Heart Failure, Renal Disease, Pharmacological Interactions, Type 1 Diabetes, Type 2 Diabetes, Pregnancy & IVF (please see OPTIFAST FERTILITY PROTOCOL for more detailed information), Hypertension & Hepatic Disease (incl Gallstones).

The OPTIFAST VLCD Clinical Treatment Protocol is a step-by-step guide on how to recommend the OPTIFAST VLCD Program to patients. If you are new to the OPTIFAST Program, we recommend reading this protocol first, followed by our supporting protocols (Management of complex cases, Preoperative, Fertility protocols). This protocol is suited to general practitioners, specialists, dietitians, pharmacists, surgeons, diabetes educators, exercise physiologists, researchers and specialist practice nurses.